Literature DB >> 10881902

Relation between cholinesterase inhibitor and Pisa syndrome.

Y T Kwak, I W Han, J Baik, M S Koo.   

Abstract

We report two patients who developed Pisa syndrome after treatment with cholinesterase inhibitors--cognition-enhancing novel agents for patients with Alzheimer's disease. Cholinergic excess could be another factor in Pisa syndrome, especially in cholinergically-imbalanced Alzheimer's disease.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10881902     DOI： 10.1016/S0140-6736(00)02412-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  12 in total

1.  Lateral trunk flexion in Parkinson's disease: EMG features disclose two different underlying pathophysiological mechanisms.

Authors:  Alessandro Di Matteo; Alfonso Fasano; Giovanna Squintani; Lucia Ricciardi; Tommaso Bovi; Antonio Fiaschi; Paolo Barone; Michele Tinazzi
Journal:  J Neurol       Date:  2010-11-16       Impact factor: 4.849

2.  Botulinum toxin type A and a rehabilitation program in the treatment of Pisa syndrome in Parkinson's disease.

Authors:  Andrea Santamato; Maurizio Ranieri; Francesco Panza; Stefano Zoccolella; Vincenza Frisardi; Vincenzo Solfrizzi; Maria Teresa Amoruso; Loredana Amoruso; Pietro Fiore
Journal:  J Neurol       Date:  2010-01       Impact factor: 4.849

3.  Pisa syndrome as presenting symptom of amyotrophic lateral sclerosis.

Authors:  Marcello Deriu; Daniela Murgia; Alessandra Paribello; Emanuele Marcia; Maurizio Melis; Giovanni Cossu
Journal:  J Neurol       Date:  2011-04-23       Impact factor: 4.849

4.  Donepezil induced antecollis in a patient with Parkinson's disease dementia.

Authors:  Yoon-Sang Oh; Joong-Seok Kim; Dong Woo Ryu; Kwang-Soo Lee
Journal:  Neurol Sci       Date:  2012-11-23       Impact factor: 3.307

Review 5.  Drug-induced Pisa syndrome (pleurothotonus): epidemiology and management.

Authors:  Toshihito Suzuki; Hisashi Matsuzaka
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 6.  An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine.

Authors:  Rita Khoury; Jayashree Rajamanickam; George T Grossberg
Journal:  Ther Adv Drug Saf       Date:  2018-01-08

Review 7.  Hyperkinetic Movement Disorder Emergencies.

Authors:  Giovanni Cossu; Carlo Colosimo
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

8.  Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.

Authors:  Ramón Cacabelos
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

9.  Risperidone Induced Pisa Syndrome in a Male Adolescent.

Authors:  Serkan Güneş; Özalp Ekinci; Meltem Çobanoğulları Direk; Veli Yıldırım; Çetin Okuyaz; Fevziye Toros
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-02-29       Impact factor: 2.582

Review 10.  Pathophysiological Concepts and Treatment of Camptocormia.

Authors:  N G Margraf; A Wrede; G Deuschl; W J Schulz-Schaeffer
Journal:  J Parkinsons Dis       Date:  2016-06-16       Impact factor: 5.568
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.